Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US0463531089
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BZ0DK8
AZN
AstraZeneca PLC
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—General · THEMEFOLIO: $TF-77
NAME
AstraZeneca PLC
ISIN
US0463531089
TICKER
AZN
MIC
XNAS
REUTERS
AZN.OQ
BLOOMBERG
AZN US
Fri, 14.03.2025       AstraZeneca
US0463531089

AstraZeneca and Erin Andrews have teamed up as part of a national public health campaign to educate and empower people to Get Body Checked Against Cancer. Erin is a passionate entrepreneur, national sports broadcaster, podcast host, hockey fan and wife — and cancer survivor. This press release features multimedia. View the full release here: https...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.03.2025       AstraZeneca
US0463531089

Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sat, 01.03.2025       AstraZeneca
US0463531089

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.02.2025       AstraZeneca
US0463531089

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint o...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       AstraZeneca
US0463531089

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) and reminds investors of the Feb. 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi &...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.02.2025       AstraZeneca
US0463531089

LOS ANGELES, Feb. 20, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws. Sharehol...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.02.2025       AstraZeneca
US0463531089

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal ri...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to cont...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 19.02.2025       AstraZeneca
GB0009895292

Das Instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY wird ex Dividende/Zinsen gehandelt am 20.02.2025 The instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY has its ex-dividend/interest day on 20.02.2025...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.02.2025       AstraZeneca
US0463531089

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Ast...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.02.2025       AstraZeneca
US0463531089

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.02.2025       AstraZeneca
GB0009895292

Das Instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY wird cum Dividende/Zinsen gehandelt am 19.02.2025 und ex Dividende/Zinsen am 20.02.2025 The instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY has its pre-dividend/interest day on 19.02.2025 and its ex-dividend/interest day on 20.02.2025...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.02.2025       AstraZeneca
US0463531089

LOS ANGELES, Feb. 18, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) have opportunity to lead the securities fraud class action lawsuit....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sat, 15.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 15, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusiv...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.02.2025       AstraZeneca
US0463531089

LOS ANGELES, Feb. 14, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN)....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.02.2025       AstraZeneca
US0463531089

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 14.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.02.2025       AstraZeneca
US0463531089

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusiv...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.02.2025       AstraZeneca
US0463531089

LOS ANGELES, Feb. 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to cont...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       AstraZeneca
US0463531089

BENSALEM, Pa., Feb. 7, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ASTRAZENECA PLC (AZN), CONTACT THE...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       AstraZeneca
US0463531089

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to reco...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.02.2025       AstraZeneca
GB0009895292

AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to conta...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 5, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       AstraZeneca
US0463531089

LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) have opportunity to lead the securities fraud class action lawsuit....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       AstraZeneca
US0463531089

LOS ANGELES, Feb. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       AstraZeneca
US0463531089

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to reco...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.02.2025       AstraZeneca
US0463531089

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company th...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sun, 02.02.2025       AstraZeneca
US0463531089

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their Options If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.01.2025       AstraZeneca
US0463531089

NEW YORK, Jan. 31, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusiv...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.01.2025       AstraZeneca
US0463531089

LOS ANGELES, Jan. 31, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN)....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.01.2025       AstraZeneca
US0463531089

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.01.2025       AstraZeneca
US0463531089

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.01.2025       AstraZeneca
US0463531089

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.01.2025       AstraZeneca
US0463531089

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.01.2025       AstraZeneca
US0463531089

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sun, 26.01.2025       AstraZeneca
US0463531089

NEW YORK, Jan. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.01.2025       AstraZeneca
US0463531089

BENSALEM, Pa., Jan. 24, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ASTRAZENECA PLC (AZN), CONTACT TH...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.01.2025       AstraZeneca
US0463531089

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to rec...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.01.2025       AstraZeneca
GB0009895292

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies MISSISSAUGA, ON, Jan. 23, 2025 /CNW/ - AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, today announced a C$820 million (US$570m) investment in Canada, cr...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.01.2025       AstraZeneca
US0463531089

LOS ANGELES, Jan. 23, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.01.2025       AstraZeneca
US0463531089

NEW YORK, Jan. 21, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusiv...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink